SCHEMBL607844

SCHEMBL607844

NC(=O)c1ccc2ccccc2c1Br

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.52
WDR5 P61964 1/20 0.48
KMT2A Q03164 2/20 0.47
ATM Q13315 1/20 0.47
LDHA P00338 1/20 0.47
KDM4E B2RXH2 4/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GAA P10253 2/20 0.46
ALDH1A1 P00352 2/20 0.46
NCEH1 Q6PIU2 1/20 0.45
MAOB P27338 1/20 0.44
HCRTR1 O43613 1/20 0.44
HCRTR2 O43614 1/20 0.44
IKBKB O14920 1/20 0.43
MMP3 P08254 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
MEN1 O00255 1/20 0.43
PARP1 P09874 2/20 0.42
HTT P42858 1/20 0.42
NR4A1 P22736 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL485599 0.84 WDR5 (0.68) POLBWDR5KMT2ALDHAKDM4E
SCHEMBL27709602 0.81 SLC9A1 (0.49) POLBWDR5KMT2AATMLDHA
SCHEMBL2016154 0.81 POLB (0.52) POLBWDR5KMT2ALDHAKDM4E
SCHEMBL31520424 0.81 POLB (0.52) POLBWDR5KMT2ALDHAKDM4E
SCHEMBL4645452 0.81 POLB (0.52) POLBWDR5KMT2ALDHAKDM4E
SCHEMBL6748668 0.80 WDR5 (0.68) POLBWDR5KMT2AATMLDHA
SCHEMBL14504216 0.80 MMP3 (0.44) POLBWDR5KMT2ALDHAKDM4E
SCHEMBL599946 0.78 WDR5 (0.50) POLBWDR5KMT2AATMLDHA
SCHEMBL356272 0.78 LDHA (0.69) WDR5KMT2ALDHAKDM4EMEN1
SCHEMBL8097610 0.78 CYP1A1 (0.57) POLBWDR5KMT2AATMLDHA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 US claimed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US claimed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP claimed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP claimed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US claimed
CN-101119717-A Substituted phenols as agents inhibiting VEGF production PTC THERAPEUTICS INC (US) 2008-02-06 CN claimed
CN-1867572-A proteasome inhibitors and methods of use thereof CEPHALON INC (US) 2006-11-22 CN claimed
EP-1660507-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2006-05-31 EP claimed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 US claimed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 WO claimed
CN-104892502-B It is used as the aryl-pyridine of aldosterone synthase inhibitors 诺华股份有限公司 2017-08-04 CN disclosed
CN-106478500-A Carboxylic acid-substituted(Miscellaneous)Aromatic ring analog derivative and its production and use 广东东阳光药业有限公司 2017-03-08 CN disclosed
EP-1660507-B2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME MILLENNIUM PHARM INC (US) 2017-01-04 EP disclosed
US-9233115-B2 Proteasome inhibitors and methods of using the same MILLENNIUM PHARMACEUTICALS INC. (US) 2016-01-12 US disclosed
EP-1660507-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2006-05-31 EP disclosed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 US disclosed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 WO disclosed
EP-1157003-A1 ACYLATED AMINOACETONITRILES AS CYSTEINE PROTEASE INHIBITORS AstraZeneca AB (SE) 2001-11-28 EP disclosed
WO-2000048992-A1 ACYLATED AMINOACETONITRILES AS CYSTEINE PROTEASE INHIBITORS ASTRAZENECA AB (SE) 2000-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 POLB 829/4885WDR5 1023/4885KMT2A 2266/4885
US-20050107307-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 POLB 829/4885WDR5 1023/4885KMT2A 2266/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 POLB 829/4885WDR5 1023/4885KMT2A 2266/4885
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production VEGFA, FLT4, FLT1 POLB 1768/4885WDR5 3104/4885KMT2A 3045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.